TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25744158

Group type: COMPARATOR
Intervention: Erythritol 20 g
Number of subjects: 185

Group type: COMPARATOR
Intervention: Erythritol 25 g
Number of subjects: 185

Group type: COMPARATOR
Intervention: Erythritol 15 g
Number of subjects: 185

Group type: COMPARATOR
Intervention: Erythritol 5 g
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Placebo (isosweet sucrose)
Number of subjects: 185
Study: 23535137

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 21370769

Group type: EXPERIMENTAL
Intervention: Additional manual therapy techniques to the temporomandibular region
Number of subjects: 43

Group type: COMPARATOR
Intervention: Usual care group (manual therapy for the cervical region)
Number of subjects: 43
Study: 19227169

Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion (ropivacaine 0.18% and fentanyl 45.5 microg x ml(‐1) at 2 ml x hr(‐1))
Number of subjects: 32

Group type: COMPARATOR
Intervention: Continuous hypodermic infusion (morphine 0.04 mg x kg(‐1) x ml(‐1) at 0.5 ml x hr(‐1); bolus: 0.5 ml x hr(‐1))
Number of subjects: 32
Study: 16877271

Group type: EXPERIMENTAL
Intervention: Niacin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12942279

Group type: EXPERIMENTAL
Intervention: IV Buscopan
Number of subjects: 73

Group type: COMPARATOR
Intervention: No muscle relaxant
Number of subjects: 73
Study: 10868317

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg bid)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Warfarin and Celecoxib
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8938878

Group type: EXPERIMENTAL
Intervention: 0.1% Diclofenac eye-drops
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 1590949

Group type: EXPERIMENTAL
Intervention: Left hemisphere lesions
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Right hemisphere lesions
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 70
Study: 3987303

Group type: EXPERIMENTAL
Intervention: Mechanical prosthetic valve (Björk‐Shiley)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bioprosthesis (Hancock porcine heterograft valve)
Number of subjects: 0
Study: 31283765

Group type: EXPERIMENTAL
Intervention: Bayesian change-point detection model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternative models (approximate Bayesian to simple heuristics)
Number of subjects: 0
Study: 29222135

Group type: EXPERIMENTAL
Intervention: Ambulatory treatment (OP)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Inpatient treatment (IP)
Number of subjects: 152
Study: 25722532

Group type: EXPERIMENTAL
Intervention: Fatigued patients with MS (n = 21)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Non-fatigued patients with MS (n = 14)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: IL-6 (pro-inflammatory cytokine)
Number of subjects: 35
Study: 24694475

Group type: EXPERIMENTAL
Intervention: Steroids alone (methylprednisolone, MP group; n=25)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Steroids plus cyclosporine A (combination group; n=23)
Number of subjects: 48
Study: 21600712

Group type: EXPERIMENTAL
Intervention: Silicone plates (Group S)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Gauze packing (Group G)
Number of subjects: 35
Study: 20128667

Group type: EXPERIMENTAL
Intervention: Ice application to the ankle joint
Number of subjects: 24
Study: 17557322

Group type: EXPERIMENTAL
Intervention: Anterior tibial post contact
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Hyperextension angles
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Femoral component flexion
Number of subjects: 11
Study: 16353397

Group type: EXPERIMENTAL
Intervention: Tinnitus self-rating scale for loudness (six-point response scale)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Tinnitus self-rating scale for annoyance (eight-point response scale)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Tinnitus self-rating scale for change (six-point response scale)
Number of subjects: 273
Study: 12014100

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 154

Group type: COMPARATOR
Intervention: Lack of physical activity
Number of subjects: 154

Group type: COMPARATOR
Intervention: Obesity
Number of subjects: 154
Study: 10594412

Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (COPA)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 75
Study: 8786250

Group type: EXPERIMENTAL
Intervention: PABA 1.5 g orally every 6 hours for 5 days with intravenous procainamide 750 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Intravenous procainamide alone
Number of subjects: 11
Study: 2190664

Group type: EXPERIMENTAL
Intervention: Primary excision and grafting
Number of subjects: 25

Group type: COMPARATOR
Intervention: Defatting the flap
Number of subjects: 25
Study: 37493

Group type: EXPERIMENTAL
Intervention: Ketotifen (2 x 1 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Ketotifen (2 x 2 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Clemastine (2 x 1 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Cromoglycate (Intal)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Ketotifen (3 and 14 days after treatment)
Number of subjects: 27
Study: 31449576

Group type: EXPERIMENTAL
Intervention: DFDBA + CM
Number of subjects: 0

Group type: COMPARATOR
Intervention: DFDBA
Number of subjects: 0
Study: 28921654

Group type: EXPERIMENTAL
Intervention: Alcohol administration (0.0 and 0.65 g/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 50
Study: 25931212

Group type: EXPERIMENTAL
Intervention: 0.1 Hz low frequency rTMS (n=21)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5 Hz high frequency rTMS (n=21)
Number of subjects: 60

Group type: COMPARATOR
Intervention: False stimulation (control group, n=18)
Number of subjects: 60
Study: 23675620

Group type: EXPERIMENTAL
Intervention: Genuine EMFs exposure (GSM cellular phone at 900 MHz, 2 W)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 26
Study: 21852542

Group type: EXPERIMENTAL
Intervention: Reslizumab 3.0 mg/kg
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 19028832

Group type: EXPERIMENTAL
Intervention: Cyclic methylprednisolone (MP) in combination with azathioprine (AZA) for 6 months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 27
Study: 18021866

Group type: EXPERIMENTAL
Intervention: Zoster vaccine
Number of subjects: 0
Study: 16338193

Group type: EXPERIMENTAL
Intervention: TX-disc
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo disc
Number of subjects: 80
Study: 12022001

Group type: EXPERIMENTAL
Intervention: Contact lens correction for myopias > 11 D
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Contact lens correction for hyperopias > 9 D
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Contact lens correction for myopias > 18 D
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Contact lens correction for hyperopias > 13 D
Number of subjects: 88

Group type: COMPARATOR
Intervention: No contact lens correction
Number of subjects: 88
Study: 10382340

Group type: EXPERIMENTAL
Intervention: Activation of the patient, reducing fear, avoiding bedrest and inactivity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 7872215

Group type: COMPARATOR
Intervention: Standard preterm formula (without long-chain polyunsaturated fatty acids)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Experimental formula (with long-chain polyunsaturated fatty acids)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Human milk fortified with protein and energy
Number of subjects: 35
Study: 2397973

Group type: EXPERIMENTAL
Intervention: Naftifine cream 1%
Number of subjects: 70

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 70
Study: 373103

Group type: EXPERIMENTAL
Intervention: Cimetidine (1.6 g/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 31405646

Group type: EXPERIMENTAL
Intervention: Vitamin D (100 μg or 4000 IU daily)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 30241993

Group type: EXPERIMENTAL
Intervention: ICBT
Number of subjects: 131

Group type: COMPARATOR
Intervention: Internet-delivered child-directed play (active control)
Number of subjects: 131

Group type: COMPARATOR
Intervention: ICBT vs Control
Number of subjects: 131
Study: 27327921

Group type: EXPERIMENTAL
Intervention: Anti-gravity gait training using the AlterG® Anti-Gravity Treadmill®
Number of subjects: 30

Group type: COMPARATOR
Intervention: Land-based gait training
Number of subjects: 30
Study: 24355401

Group type: EXPERIMENTAL
Intervention: TAU plus TMC plus incentives for session attendance (TMC+)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: TAU plus Telephone Monitoring and Counseling (TMC)
Number of subjects: 321

Group type: COMPARATOR
Intervention: IOP treatment as usual (TAU)
Number of subjects: 321
Study: 22933802

Group type: EXPERIMENTAL
Intervention: Magnetoencephalography in young individuals
Number of subjects: 20

Group type: COMPARATOR
Intervention: Magnetoencephalography in middle-aged individuals
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hierarchical regression analysis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FA of the uncinate fasciculus
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Age-related reductions in left-lateralization of language responses
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: N400 reductions
Number of subjects: 20
Study: 20100765

Group type: EXPERIMENTAL
Intervention: Nutrition labeling on menus
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no nutrition labeling)
Number of subjects: 99
Study: 17631219

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 75
Study: 16157401

Group type: EXPERIMENTAL
Intervention: Continuous accelerated postoperative irradiation (p-CAIR) - 63 Gy in 1.8 Gy fractions 7-days-a-week over 5 weeks
Number of subjects: 175

Group type: COMPARATOR
Intervention: Conventional fractionated postoperative radiotherapy (p-CF) - 63 Gy in 1.8 Gy fractions 5-days-a-week over 7 weeks
Number of subjects: 175
Study: 12916135

Group type: EXPERIMENTAL
Intervention: Female condom
Number of subjects: 1442

Group type: COMPARATOR
Intervention: Male condom
Number of subjects: 1442

Group type: COMPARATOR
Intervention: Comparison of STD occurrence
Number of subjects: 1442

Group type: COMPARATOR
Intervention: Comparison of incidence rates
Number of subjects: 1442
Study: 10503688

Group type: EXPERIMENTAL
Intervention: Postnatal penicillin prophylaxis (PP)
Number of subjects: 10998
Study: 7537170

Group type: EXPERIMENTAL
Intervention: Astemizole-D (10 mg astemizole plus 240 mg pseudoephedrine) once daily
Number of subjects: 204

Group type: COMPARATOR
Intervention: Beclomethasone nasal spray (0.05 mg/ml) two puffs/nostril twice daily
Number of subjects: 204
Study: 2109515

Group type: EXPERIMENTAL
Intervention: Norinyl 1/35
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lo-Ovral
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Noriday 1/50
Number of subjects: 150
Study: 399592

Group type: EXPERIMENTAL
Intervention: Hydrallazine
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Oxprenolol plus Hydrallazine
Number of subjects: 5

Group type: COMPARATOR
Intervention: Oxprenolol alone
Number of subjects: 5

Group type: COMPARATOR
Intervention: Hydrallazine alone
Number of subjects: 5
Study: 31913907

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) for stage I NSCLC
Number of subjects: 174
Study: 31307651

Group type: EXPERIMENTAL
Intervention: Brachial plexus group
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Lumbosacral plexus group
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging group
Number of subjects: 163

Group type: COMPARATOR
Intervention: Overall findings
Number of subjects: 163
Study: 27615161

Group type: EXPERIMENTAL
Intervention: Ferric citrate
Number of subjects: 412

Group type: COMPARATOR
Intervention: Active control (sevelamer carbonate and/or calcium acetate)
Number of subjects: 412
Study: 25538152

Group type: EXPERIMENTAL
Intervention: Community-based exercise (19 weeks, 3 times/week)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stretching (control group)
Number of subjects: 40
Study: 23649216

Group type: EXPERIMENTAL
Intervention: Chemonucleolysis
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 100
Study: 20615905

Group type: EXPERIMENTAL
Intervention: Reduced eGFR in participants aged 18-29 years (2.6%)
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Reduced eGFR in participants aged 30-41 years (7.4%)
Number of subjects: 771

Group type: COMPARATOR
Intervention: Dipstick proteinuria of 1+ or greater in cases (27%)
Number of subjects: 771

Group type: COMPARATOR
Intervention: Haematuria in cases (24%)
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Hypertension and residence at lower altitude
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Occupational history
Number of subjects: 771
Study: 19761652

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg Zn2+/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 26
Study: 16720138

Group type: EXPERIMENTAL
Intervention: 1 g cefazolin (group A)
Number of subjects: 277

Group type: COMPARATOR
Intervention: 10 mL isotonic sodium chloride solution (group B; control)
Number of subjects: 277
Study: 15381645

Group type: EXPERIMENTAL
Intervention: US patients (intervention group)
Number of subjects: 26003

Group type: COMPARATOR
Intervention: Canadian patients (control group)
Number of subjects: 26003

Group type: EXPERIMENTAL
Intervention: Country (US vs Canada)
Number of subjects: 26003
Study: 11760033

Group type: EXPERIMENTAL
Intervention: 0.1% dexamethasone phosphate eye gel
Number of subjects: 236

Group type: COMPARATOR
Intervention: 1% prednisolone acetate eye suspension
Number of subjects: 236
Study: 9159563

Group type: EXPERIMENTAL
Intervention: Frusemide administered as a slow-rate infusion
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Frusemide administered in combination with 2 g of probenecid
Number of subjects: 7

Group type: COMPARATOR
Intervention: Frusemide bolus dose
Number of subjects: 7
Study: 8518372

Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 36

Group type: COMPARATOR
Intervention: Isosorbide dinitrate
Number of subjects: 36
Study: 3683453

Group type: EXPERIMENTAL
Intervention: 40 mg of mixed gangliosides (Cronassial)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 31838596

Group type: EXPERIMENTAL
Intervention: Probiotic milk (Lactobacillus paracasei SD1) daily (group II)
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: Probiotic milk (Lactobacillus paracasei SD1) triweekly (group III)
Number of subjects: 487

Group type: COMPARATOR
Intervention: Placebo milk (group I)
Number of subjects: 487
Study: 31033133

Group type: EXPERIMENTAL
Intervention: Wheat extract oil (WEO)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 28034704

Group type: EXPERIMENTAL
Intervention: Oral antioxidants (2 g ascorbate, 1.2 g N-acetylcysteine, 600 mg lipoic acid, 30 mg beta carotene)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no antioxidants)
Number of subjects: 10
Study: 25421868

Group type: EXPERIMENTAL
Intervention: Evening dosing of naftopidil
Number of subjects: 143

Group type: COMPARATOR
Intervention: Morning dosing of naftopidil
Number of subjects: 143
Study: 24024769

Group type: EXPERIMENTAL
Intervention: Chromium nicotinate 50 μg (NC50)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Chromium nicotinate 200 μg (NC200)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (NC0)
Number of subjects: 56
Study: 21454723

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 4351

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 4351

Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 4351
Study: 18321515

Group type: EXPERIMENTAL
Intervention: Psychological treatment before infertility treatment
Number of subjects: 140
Study: 16490000

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 14751919

Group type: EXPERIMENTAL
Intervention: Conservative treatments for prostate cancer
Number of subjects: 129
Study: 11397883

Group type: EXPERIMENTAL
Intervention: Estring treatment (7.5 microg per 24 h)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 70
Study: 9268185

Group type: EXPERIMENTAL
Intervention: Plasma response to activated protein C (APC)
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: APC-ratio
Number of subjects: 4000
Study: 8503751

Group type: EXPERIMENTAL
Intervention: Early, intensive, gait‐focused physical therapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Early, intensive and conventional therapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Routine conventional therapy that started later and was not intense
Number of subjects: 27
Study: 3103901

Group type: EXPERIMENTAL
Intervention: Calcium gluconate
Number of subjects: 48

Group type: COMPARATOR
Intervention: Calcium pyrrolidone carboxylate
Number of subjects: 48
Study: 28750549

Group type: EXPERIMENTAL
Intervention: Error augmentation
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Error minimization
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional treadmill training (control)
Number of subjects: 47
Study: 27404642

Group type: EXPERIMENTAL
Intervention: Group meetings with 11 personal motivational calls
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Group meetings with 11 automated motivational messages
Number of subjects: 288

Group type: COMPARATOR
Intervention: Group meetings with no calls
Number of subjects: 288
Study: 23956009

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) systems including optical frequency domain imaging (OFDI) and μOCT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) systems
Number of subjects: 0
Study: 21848863

Group type: EXPERIMENTAL
Intervention: Urokinase 25,000 IU in both arterial and venous lines for each thrombotic event (Group A)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Urokinase 100,000 IU in both arterial and venous lines for each thrombotic event (Group B)
Number of subjects: 72
Study: 20833862

Group type: EXPERIMENTAL
Intervention: Multidisciplinary falls prevention programme (including physiotherapy, occupational therapy, nurse, medical review, referral to specialists)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Falls prevention information leaflet
Number of subjects: 364
Study: 18369669

Group type: EXPERIMENTAL
Intervention: Hybrid Bond
Number of subjects: 50

Group type: COMPARATOR
Intervention: Xeno III
Number of subjects: 50
Study: 15626550

Group type: EXPERIMENTAL
Intervention: Exercise training for 6 months
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 115
Study: 12760507

Group type: EXPERIMENTAL
Intervention: Tetracycline fibres (TCF) applied in 5 pockets
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mechanical treatment only (scaling and root planing)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tetracycline fibres (TCF)
Number of subjects: 10
Study: 11689389

Group type: EXPERIMENTAL
Intervention: Paricalcitol dosing based on baseline intact parathyroid hormone (iPTH; PTH/80) level
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Paricalcitol dosing based on patient body weight (0.04 microgram/kg)
Number of subjects: 125
Study: 9393221

Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 5176

Group type: COMPARATOR
Intervention: Dual therapy
Number of subjects: 5176

Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 5176

Group type: COMPARATOR
Intervention: Antiretroviral combination therapies (1991-1996)
Number of subjects: 5176
Study: 8180867

Group type: EXPERIMENTAL
Intervention: 100% of 150 ml of nonionic contrast agent (ivoversol, 320 mg/ml)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 75% of 150 ml of nonionic contrast agent (ivoversol, 320 mg/ml)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 65% of 150 ml of nonionic contrast agent (ivoversol, 320 mg/ml)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 50% of 150 ml of nonionic contrast agent (ivoversol, 320 mg/ml)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 30% of 150 ml of nonionic contrast agent (ivoversol, 320 mg/ml)
Number of subjects: 45
Study: 3286517

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg b.i.d. for UTI (22 cases)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg b.i.d. for UTI (20 cases)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg s.i.d. for UTI (20 cases)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg b.i.d. for RTI (10 cases)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg b.i.d. for RTI (20 cases)
Number of subjects: 92
Study: 29747540

Group type: EXPERIMENTAL
Intervention: real a‐tDCS (stimulation, 1.5 mA for 30 minutes)
Number of subjects: 40

Group type: COMPARATOR
Intervention: sham a‐tDCS
Number of subjects: 40
Study: 26507180

Group type: EXPERIMENTAL
Intervention: Awake-regional anaesthesia
Number of subjects: 722

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 722
Study: 24722763

Group type: EXPERIMENTAL
Intervention: ASD group
Number of subjects: 2

Group type: COMPARATOR
Intervention: TD group
Number of subjects: 2
Study: 24418877

Group type: EXPERIMENTAL
Intervention: 40 g daily whole bean soy consumption for 18 months
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (normo-cholesterolemic women)
Number of subjects: 90
Study: 20453692

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 0
Study: 19083462

Group type: EXPERIMENTAL
Intervention: 600 microg/d of vitamin K in the form of phylloquinone (K(1))
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 14